{"id":12579,"date":"2025-11-07T07:00:00","date_gmt":"2025-11-07T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/"},"modified":"2026-05-05T22:11:16","modified_gmt":"2026-05-05T20:11:16","slug":"irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/","title":{"rendered":"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>G\u00f6teborg den 7 november 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelar idag att tv\u00e5 abstracts har accepterats f\u00f6r presentation vid den internationella konferensen AD\/PD 2026, som h\u00e5lls i K\u00f6penhamn den 17-21 mars.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>\u201dVi ser mycket fram emot att medverka p\u00e5 AD\/PD, en av v\u00e4rldens ledande vetenskapliga m\u00f6tesplatser inom Parkinsons sjukdom. Det ger oss m\u00f6jlighet att aktivt bidra till forskningen, samtidigt som vi st\u00e4rker v\u00e5rt n\u00e4tverk och \u00f6kar f\u00f6rtroendet f\u00f6r v\u00e5r pipeline\u201d, s\u00e4ger Kristina Torfg\u00e5rd, vd f\u00f6r IRLAB.<\/p>\n<p>Bolagets tv\u00e5 abstract har titlarna:<\/p>\n<ul>\n<li><em>Results from REACT-PD &#8211; a randomized, placebo-controlled, multi-centre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson\u2019s disease. <\/em>F\u00f6rfattare: Joakim Tedroff, Fredrik Hansson, Erik Werner, Olivia Vu Van, Johanna Landstr\u00f6m, Nicholas Waters, Clas Sonesson och Susanna Waters.<\/li>\n<li><em>Searching for novel CNS therapies in Parkinson\u2019s and Alzheimer\u2019s disease using integrative screening process (ISP): An AI\/ML driven phenotypic drug discovery platform. <\/em>F\u00f6rfattare: Susanna Waters, Peder Svensson, Nicholas Waters, Erik Werner, Daniel Andersson, Fredrik Wallner, Joakim Tedroff, Clas Sonesson och Sebastian Oleszko.<\/li>\n<\/ul>\n<p>Abstracten kommer att presenteras av Susanna Waters, Director Systems Pharmacology, Sebastian Oleszko, Research Scientist, AI &amp; Computational Biology och Joakim Tedroff, Chief Medical Officer.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-4b40c0227696\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information<\/strong><\/p>\n<hr\/>\n<p>Kristina Torfg\u00e5rd, VD<br \/>Tel: +46 730 60 70 99<br \/>E-post: <a href=\"mailto:kristina.torfgard@irlab.se\" rel=\"noopener\" target=\"_blank\">kristina.torfgard@irlab.se<\/a><br \/>\u00a0<br \/>Nicholas Waters, EVP och Head of R&amp;D<br \/>Tel: +46\u00a0730 75 77 01<br \/>E-post: <a href=\"mailto:nicholas.waters@irlab.se\" rel=\"noopener\" target=\"_blank\">nicholas.waters@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-a19a8f82b785\">\n<p><strong class=\"mfn-heading-1\">Om IRLAB<\/strong><\/p>\n<hr\/>\n<p>IRLAB uppt\u00e4cker och utvecklar en portf\u00f6lj av transformativa behandlingar f\u00f6r alla stadier av Parkinsons sjukdom. Bolaget har sitt ursprung i Nobelpristagaren Prof. Arvid Carlssons forskargrupp och uppt\u00e4ckten av ett samband mellan st\u00f6rningar i hj\u00e4rnans signalsubstanser och hj\u00e4rnans sjukdomar. Mesdopetam (IRL790), under utveckling f\u00f6r behandling av levodopa-inducerade dyskinesier, har slutf\u00f6rt Fas IIb och \u00e4r i f\u00f6rberedelse f\u00f6r Fas III. Pirepemat (IRL752), befinner sig f\u00f6r n\u00e4rvarande i Fas IIb, och utv\u00e4rderas f\u00f6r sin effekt p\u00e5  fallfrekvens vid Parkinson. IRL757, en substans som utvecklas f\u00f6r behandling av apati vid neurodegenerativa sjukdomar, befinner sig i Fas I. Dessutom utvecklar bolaget de tv\u00e5 prekliniska programmen IRL942 och IRL1117 mot Fas I-studier. IRLAB:s pipeline har genererats av bolagets egenutvecklade systembiologibaserade forskningsplattform Integrative Screening Process (ISP). IRLAB har sitt huvudkontor i Sverige och \u00e4r noterat p\u00e5 Nasdaq Stockholm (IRLAB A). F\u00f6r mer information, bes\u00f6k\u00a0<a href=\"http:\/\/www.irlab.se\/\" rel=\"noopener\" target=\"_blank\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/7f9c115b-aaee-4c9f-9f36-087c69e8a0a7\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20-e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar.pdf\" rel=\"noopener\" target=\"_blank\">IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>G\u00f6teborg den 7 november 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelar idag att tv\u00e5 abstracts har accepterats f\u00f6r presentation vid den internationella konferensen AD\/PD 2026, som h\u00e5lls i K\u00f6penhamn den 17-21 mars.<\/p>\n","protected":false},"template":"","class_list":["post-12579","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-lang-en_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg den 7 november 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelar idag att tv\u00e5 abstracts har accepterats f\u00f6r presentation vid den internationella konferensen AD\/PD 2026, som h\u00e5lls i K\u00f6penhamn den 17-21 mars.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T20:11:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/\",\"name\":\"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2025-11-07T06:00:00+00:00\",\"dateModified\":\"2026-05-05T20:11:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB","og_description":"G\u00f6teborg den 7 november 2025 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelar idag att tv\u00e5 abstracts har accepterats f\u00f6r presentation vid den internationella konferensen AD\/PD 2026, som h\u00e5lls i K\u00f6penhamn den 17-21 mars.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/","og_site_name":"IRLAB","article_modified_time":"2026-05-05T20:11:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/","name":"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2025-11-07T06:00:00+00:00","dateModified":"2026-05-05T20:11:16+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-far-tva-abstracts-accepterade-till-ad-pd-2026-den-20e-internationella-konferensen-om-alzheimers-och-parkinsons-sjukdomar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB f\u00e5r tv\u00e5 abstracts accepterade till AD\/PD&#x2122; 2026: Den 20:e internationella konferensen om Alzheimers och Parkinsons sjukdomar"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/12579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=12579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}